Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

por Rowland, A, Dias, M M, Wiese, M D, Kichenadasse, G, McKinnon, R A, Karapetis, C S, Sorich, M J
Publicado 2015